Laura Joszt, MA

March 06, 2024

Biosimilars Wyost and Jubobonti were approved as interchangeable for Xgeva and Prolia but launch will depend on the outcome of litigation between reference product manufacturers.

July 07, 2023

FDA's action, based on confirmatory evidence showing slowed disease progression, follows a January 2023 accelerated approval.

June 12, 2023

Results of a new study offer additional support for clinical guidelines to favor one therapy over another, authors suggest.